



liberty health sciences

Liberty Announces 11th Dispensary Opening in Florida, Completion of Phase 1 Construction at Liberty 360 and Strategic Changes

Toronto, ON – February 28, 2019 — Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: [LHSIF](https://www.libertyhealthsciences.com)) (www.libertyhealthsciences.com) (“Liberty” or the “Company”), a provider of high quality cannabis, announced today that it will be opening its latest dispensary in Orange Park, Florida, on March 1, 2019 pending Florida Department of Health (the “DOH”) approvals. In supporting the growth of its dispensary openings, the Company also announced that the first phase of its construction at its Liberty 360 Innovation Campus (“Liberty 360”) in Gainesville, Florida has been completed, including required inspections by the DOH, which provides the Company with an additional 80,000 square feet of cultivation space. The Company also announces that it continues to work towards increasing its directors and senior executives based in the United States, to more closely align with the US geographical focus of its business, as previously announced in its press releases of February 12 and 22, 2019.

Orange Park Dispensary

Located at 1907-3 Wells Road in Orange Park, Florida, Liberty’s newest dispensary will be open Monday through Friday, 10 a.m. to 7 p.m., Saturday, 10 a.m. to 5 p.m., and Sunday 12 p.m. to 5 p.m. The 4,500 square foot building includes two large waiting rooms, two private consultation rooms and state-of-the-art product displays, all situated inside a modern-style dispensary. The dispensary will service the Jacksonville area, including the neighboring communities of Fleming Island, Ridgewood, Doctors Inlet, Orange Park South, Lakeside and Bellair-Meadowbrook Terrace.

After the opening of the Orange Park location, Liberty will operate eleven dispensaries in the following cities across Florida, including: Dania Beach, Merritt Island, Miami, North Miami, Palm Harbor, Port St. Lucie, St. Petersburg, Summerfield, Tampa (Hyde Park) and Winter Haven. Liberty also continues to offer same-day delivery service across the State of Florida in select areas.

“At our Orange Park dispensary, we continue to fulfill our promise to customers by offering the 1.6 million people in the Jacksonville area access to the highest quality medical marijuana in the State of Florida,” Victor Mancebo, Interim Chief Executive Officer, said.

Liberty 360 Phase 1 Completion

At the Company’s Liberty 360 facility, the first phase of planned construction was completed and approved for operations by the DOH. This adds 80,000 square feet of greenhouses to Liberty’s property for a total of 150,000 square feet of cultivation space across its facilities in Alachua and Gainesville, Florida. The second phase of construction is expected to be completed in April 2019, pending required approvals by the DOH. Liberty has begun moving its cultivation activities from

its Chestnut Hill facility to its Liberty 360 facility, but will continue to use its Chestnut Hill facility as flexible cultivation space.

“Liberty is now beginning to realize its plan of becoming one of the largest cultivators in the State of Florida with our completion of this first phase of construction,” said Victor Mancebo. “We look forward to the completing our second phase of construction at Liberty 360 to support the immense growth in our dispensaries and our sales.”

Strategic Changes

In accordance with the strategy to increase its directors and senior executives based in the United States, Aaron Serruya and Michael Galloro will be stepping down from the Board of Directors (the “Board”), effective immediately. The Company is pleased to announce the appointment of Jeremy Straub to the Board to fill one of the vacancies created by these resignations, and will be continuing its search for an additional qualified and independent board member to fill the other vacancy. Mr. Straub will also be replacing Mr. Galloro as Chair of the Board’s Audit Committee. The Board wishes to thank Mr. Serruya and Mr. Galloro for their contributions.

Jeremy Straub is the Founder and Chief Executive Officer of Coastal Wealth, a financial firm headquartered in Fort Lauderdale, Florida, and also owns a portfolio of other complementary companies such as Coastal Wealth Property Casualty and Coastal Wealth Benefits Solutions. Mr. Straub earned his Bachelor of Arts degree from Moravian College in Bethlehem, Pennsylvania, and holds a variety of other security licenses and designations in the field of finance. Prior to Coastal Wealth, Mr. Straub spent 15 years at Fortune 500 financial company as an executive, and after launching Coastal Wealth in 2016, he quickly grew the business into the 14-office, 300-person team that it is today.

About Liberty Health Sciences Inc.

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty’s measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers’ well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual

results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Media Contacts:

Dwain Schenck
(203) 223-5230
dwain@schenckstrategies.com

Victor Mancebo
Interim Chief Executive Officer
(386) 462-0141
VMancebo@libertyhealthsciences.com